Molinié Vincent, Hervé Jean Marie, Lugagne Pierre Marie, Lebret Thierry, Botto Henry
Department of Pathology, Hôpital Saint-Joseph, Paris, France.
BJU Int. 2006 May;97(5):1109-15. doi: 10.1111/j.1464-410X.2006.06069.x.
To investigate the potential utility of a new combined immunostaining technique for diagnosing prostate cancer from histological analysis of needle biopsy specimens.
Tissue was immunostained with a combination of antibodies against a basal cell marker (p63), and an enzyme commonly overexpressed in prostate cancer (p504s), on 63 small prostate cancer foci (<1 mm) and 109 cases of ambiguous lesions observed in needle biopsies.
After p63/p504s immunostaining, 93% of the ambiguous lesions (102/109) were classified. The final diagnoses retained were: 92 prostate cancers, seven atypical small acinar proliferations suspected of being malignant but undiagnosed, 21 prostatic intraepithelial neoplasia, five atypical adenomatous hyperplasia, and 36 atrophic benign mimickers of cancer.
Combining p504s as a positive marker for prostate cancer and p63 as a negative marker might improve diagnostic performance, sensitivity and specificity, and lead to fewer false-negative results. This simple immunostaining procedure should reduce the percentage of residual ambiguous lesions and the need for additional biopsies.
通过对穿刺活检标本进行组织学分析，研究一种新的联合免疫染色技术在诊断前列腺癌方面的潜在效用。
对63个小前列腺癌病灶（<1mm）以及穿刺活检中观察到的109例疑难病变组织，使用抗基底细胞标志物（p63）抗体和前列腺癌中通常过表达的一种酶（p504s）进行联合免疫染色。
p63/p504s免疫染色后，93%的疑难病变（102/109）得以分类。最终确诊结果为：92例前列腺癌，7例疑似恶性但未确诊的非典型小腺泡增生，21例前列腺上皮内瘤变，5例非典型腺瘤样增生，以及36例萎缩性良性癌样病变。
将作为前列腺癌阳性标志物的p504s和作为阴性标志物的p63联合使用，可能会提高诊断效能、敏感性和特异性，并减少假阴性结果。这种简单的免疫染色程序应能降低残留疑难病变的比例以及额外活检的必要性。
